title: Sequence of treatment in locally advanced and metastatic renal cell carcinoma.
abstract: The spectrum of drugs that have shown activity in advanced or metastatic renal cell carcinoma (RCC) has led to a debate on the optimal sequence of treatments. There is agreement on recommending targeted agents as the standard of care in this disease. Uncertainty, however, remains on the best first-line drug choice. Physicians and patients may select sunitinib, bevacizumab in combination with interferon-alpha (IFN-α), pazopanib, or-in poor risk patients-temsirolimus. There are also a variety of therapies with proven efficacy on hand in the second-line setting: sorafenib, pazopanib, axitinib, and everolimus. While most randomized RCC trials assessed progression free survival (PFS) as primary endpoint, some agents were shown to improve median overall survival (OS), and given in sequence they have extended the life expectancy of RCC patients from 13 months in the cytokine era to over 30 months. Despite the progress made, there are sobering aspects to the oncologic success story in RCC, as the new treatments do not obtain an objective response or disease stabilization (SD) in all patients. There are also as yet no predictors to select patients who might benefit and those who are primary resistant to specific drugs, and ultimately almost all patients will experience disease progression. Bearing inevitable treatment failure in mind, availability of further drugs and switching therapy while the patient is in a condition to continue pharmacotherapy is essential. Of note, depending on the setting, only 33-59% of patients receive second-line treatment. In this review we present data on first-, second-, and third-line treatment in RCC, and discuss the difficulties in their interpretation in the context of treatment sequence. We summarize biological aspects and discuss mechanisms of resistance to anti-angiogenic therapy and their implications for treatment selection.
authors.affiliation: Division of Oncology/Haematology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Fischer
authors.affiliation: Division of Oncology/Haematology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
authors.forename: Silke
authors.initials: S
authors.lastname: Gillessen
authors.affiliation: Division of Oncology/Haematology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
authors.forename: Christian
authors.initials: C
authors.lastname: Rothermundt
keywords: Algorithms; carcinoma; molecular targeted therapy; renal cell
references.citation: Nature. 2011 Jan 13;469(7329):156-7
references.pmid: 21228852
references.citation: Cancer Cell. 2005 Oct;8(4):299-309
references.pmid: 16226705
references.citation: Lancet. 2007 Jul 14;370(9582):143-52
references.pmid: 17630037
references.citation: Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
references.pmid: 19967539
references.citation: Urology. 2014 May;83(5):1129-34
references.pmid: 24767525
references.citation: Lancet Oncol. 2013 Nov;14(12):1233-42
references.pmid: 24140184
references.citation: Eur Radiol. 2013 Mar;23 (3):632-9
references.pmid: 22918564
references.citation: Clin Genitourin Cancer. 2015 Apr;13(2):150-5
references.pmid: 25458371
references.citation: Eur Urol. 2015 May;67(5):913-24
references.pmid: 25616710
references.citation: Nat Med. 2004 Aug;10(8):858-64
references.pmid: 15235597
references.citation: Lancet Oncol. 2014 Mar;15(3):245-6
references.pmid: 24556039
references.citation: Oncology. 2015;88(1):1-8
references.pmid: 25247774
references.citation: Oncologist. 2008 Aug;13(8):876-85
references.pmid: 18695260
references.citation: N Engl J Med. 2014 May 1;370(18):1769-70
references.pmid: 24785224
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1529-39
references.pmid: 18316578
references.citation: Cancer. 2013 Oct 15;119(20):3636-43
references.pmid: 23913744
references.citation: J Clin Oncol. 2014 Mar 10;32(8):760-7
references.pmid: 24297950
references.citation: Ann Oncol. 2006 Oct;17 (10 ):1523-8
references.pmid: 16873425
references.citation: J Natl Cancer Inst. 2012 Oct 17;104(20):1534-41
references.pmid: 22927506
references.citation: Oncogene. 2004 Apr 19;23(18):3151-71
references.pmid: 15094765
references.citation: Clin Cancer Res. 2004 Sep 15;10 (18 Pt 2):6388S-92S
references.pmid: 15448036
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Cochrane Database Syst Rev. 2013 Dec 18;(12):CD008792
references.pmid: 24347031
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references.pmid: 16278481
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1525-35
references.pmid: 20501804
references.citation: Clin Cancer Res. 2010 Mar 1;16(5):1348-54
references.pmid: 20179240
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553
references.citation: J Clin Oncol. 2013 Oct 20;31(30):3791-9
references.pmid: 24019545
references.citation: Onkologie. 2011;34(6):310-4
references.pmid: 21625184
references.citation: Ann Oncol. 2012 Jun;23 (6):1549-55
references.pmid: 22056973
references.citation: J Clin Oncol. 2014 May 10;32(14 ):1412-8
references.pmid: 24687826
references.citation: Nat Biotechnol. 2007 Aug;25(8):911-20
references.pmid: 17664940
references.citation: BJU Int. 2012 Jan;109(2):200-6
references.pmid: 22212284
references.citation: Clin Genitourin Cancer. 2012 Sep;10(3):153-8
references.pmid: 22551785
references.citation: Gut. 2013 May;62(5):751-9
references.pmid: 22773551
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Natl Cancer Inst. 2002 May 1;94(9):652-61
references.pmid: 11983753
references.citation: Cancer J. 2013 Jul-Aug;19(4):348-52
references.pmid: 23867517
references.citation: Cancer Res. 2011 Mar 1;71(5):1858-70
references.pmid: 21363922
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Breast Cancer Res Treat. 2011 Feb;125(3):775-84
references.pmid: 21132360
references.citation: Cancer Res. 2005 Aug 15;65(16):7052-8
references.pmid: 16103051
references.citation: Nat Rev Clin Oncol. 2011 Aug 09;8(10):597-610
references.pmid: 21826082
references.citation: Cancer. 2010 Sep 15;116(18):4256-65
references.pmid: 20549832
references.citation: Oncogene. 2004 Jul 22;23(33):5654-63
references.pmid: 15133498
references.citation: J Clin Invest. 2003 Oct;112(8):1134-6
references.pmid: 14561696
references.citation: N Engl J Med. 2012 Mar 8;366(10):883-92
references.pmid: 22397650
references.citation: Ann Oncol. 2011 Mar;22(3):657-63
references.pmid: 20870911
references.citation: Cancer Res. 2006 Aug 15;66(16):7854-8
references.pmid: 16912157
references.citation: Nat Rev Cancer. 2008 Aug;8(8):592-603
references.pmid: 18650835
references.citation: Lancet Oncol. 2013 May;14(6):552-62
references.pmid: 23598172
references.citation: Cell. 2013 Dec 5;155(6):1309-22
references.pmid: 24315100
references.citation: Am Soc Clin Oncol Educ Book. 2014;:e228-38
references.pmid: 24857107
references.citation: Cancer Cell. 2009 Mar 3;15(3):220-31
references.pmid: 19249680
references.citation: J Clin Invest. 1990 Aug;86(2):670-4
references.pmid: 2384608
references.citation: J Clin Oncol. 2010 May 1;28(13):2137-43
references.pmid: 20368558
references.citation: Gynecol Oncol. 2004 Aug;94(2):409-15
references.pmid: 15297181
references.citation: Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42
references.pmid: 23377372
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: J Clin Oncol. 2012 Feb 10;30(5):482-7
references.pmid: 22231040
references.citation: Eur Urol. 2014 May;65(5):1014-5
references.pmid: 24646500
references.citation: J Clin Oncol. 2004 Jan 15;22(2):229-37
references.pmid: 14657227
references.citation: J Clin Oncol. 1999 Aug;17(8):2530-40
references.pmid: 10561319
references.citation: J Clin Oncol. 2013 Oct 20;31(30):3746-8
references.pmid: 24019543
references.citation: Clin Transl Oncol. 2014 Dec;16(12):1043-50
references.pmid: 25274276
references.citation: Lancet. 2011 Dec 3;378(9807):1931-9
references.pmid: 22056247
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3312-8
references.pmid: 19451442
references.citation: Lancet. 1999 Jan 2;353(9146):14-7
references.pmid: 10023944
references.citation: Cancer. 2010 Dec 1;116(23 ):5400-6
references.pmid: 21105118
references.citation: Eur Urol. 2015 Apr;67(4):740-9
references.pmid: 24882670
references.citation: J Clin Oncol. 2002 Jan 1;20(1):289-96
references.pmid: 11773181
references.citation: J Clin Invest. 2008 Sep;118(9):3065-74
references.pmid: 18725988
references.citation: J Clin Pharmacol. 2013 May;53(5):491-504
references.pmid: 23553560
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1280-9
references.pmid: 19171708
references.citation: J Clin Oncol. 2005 Jan 1;23 (1):133-41
references.pmid: 15625368
references.citation: Lancet. 2007 Dec 22;370(9605):2103-11
references.pmid: 18156031
references.citation: Clin Genitourin Cancer. 2013 Dec;11(4):441-50
references.pmid: 23856102
references.citation: N Engl J Med. 2014 Jul 31;371(5):424-33
references.pmid: 24881730
references.citation: J Clin Oncol. 2010 May 1;28(13):2144-50
references.pmid: 20368553
references.citation: Eur J Cancer. 2013 Apr;49(6):1287-96
references.pmid: 23321547
references.citation: Eur J Cancer. 2012 Feb;48(3):333-9
references.pmid: 22209391
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: Br J Cancer. 2011 Nov 22;105(11):1635-9
references.pmid: 22033275
references.citation: Mol Cancer Ther. 2015 Feb;14 (2):542-52
references.pmid: 25477325
references.citation: N Engl J Med. 1998 Apr 30;338(18):1272-8
references.pmid: 9562581
references.citation: Br J Cancer. 2014 Sep 9;111(6):1047-53
references.pmid: 24800947
references.citation: Eur Urol. 2012 Feb;61(2):307-16
references.pmid: 22055147
references.citation: Eur J Cancer. 2013 Jun;49(9):2134-42
references.pmid: 23518211
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: Clin Genitourin Cancer. 2013 Jun;11(2):128-33
references.pmid: 23332872
references.citation: Neuro Oncol. 2005 Oct;7(4):452-64
references.pmid: 16212810
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5422-8
references.pmid: 18936475
references.citation: Ann Oncol. 2014 Sep;25 Suppl 3:iii49-56
references.pmid: 25210086
references.citation: N Engl J Med. 2008 Jul 24;359(4):366-77
references.pmid: 18596266
references.citation: J Clin Oncol. 2006 Jan 1;24(1):1-3
references.pmid: 16330665
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Lancet Oncol. 2013 Dec;14(13):1287-94
references.pmid: 24206640
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references.pmid: 20100962
references.citation: Br J Cancer. 2004 Mar 22;90(6):1156-62
references.pmid: 15026795
references.citation: Br J Cancer. 2010 Mar 2;102(5):803-9
references.pmid: 20145618
references.citation: J Clin Oncol. 2014 Sep 1;32(25):2765-72
references.pmid: 25049330
references.citation: Urology. 2010 Aug;76(2):430-4
references.pmid: 20223508
references.citation: Eur J Cancer. 2013 May;49(8):1898-904
references.pmid: 23490648
references.citation: N Engl J Med. 2013 Aug 22;369(8):722-31
references.pmid: 23964934
references.citation: Cancer. 2007 Dec 1;110(11):2468-77
references.pmid: 17932908
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 13;98 (4):1387-92
references.pmid: 11171960
references.citation: Neoplasia. 2000 Jul-Aug;2(4):306-14
references.pmid: 11005565
references.citation: Cancer J Sci Am. 2000 Feb;6 Suppl 1:S93-8
references.pmid: 10685667
references.citation: Lancet Oncol. 2014 Mar;15(3):286-96
references.pmid: 24556040
references.citation: N Engl J Med. 2013 Jul 18;369(3):213-23
references.pmid: 23863050
references.citation: Oncology. 2013;85(1):8-13
references.pmid: 23797151
references.citation: Lancet Oncol. 2013 Dec;14(13):1245-6
references.pmid: 24206641
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: Crit Rev Oncol Hematol. 2012 Jun;82(3):323-37
references.pmid: 21733715
references.citation: Curr Biol. 2004 Jul 27;14(14):1296-302
references.pmid: 15268862
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381
references.citation: Eur Urol. 2015 Jan;67(1):100-10
references.pmid: 24841777
references.citation: J Clin Oncol. 2008 Aug 1;26(22):3743-8
references.pmid: 18669461
references.citation: J Urol. 2009 Jul;182(1):29-34; discussion 34
references.pmid: 19447417
references.citation: Semin Oncol. 2013 Aug;40(4):465-71
references.pmid: 23972710
references.citation: Eur Urol. 2010 Dec;58(6):906-11
references.pmid: 20884115